Comparison of inhibitory effect of 17-DMAG nanoparticles and free 17-DMAG in HSP90 gene expression in lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 20, 2014, Pages 8693-8698

  Mellatyar, Hassan ^a   Akbarzadeh, Abolfazl ^a   Rahmati, Mohammad ^b   Ghalhar, Masoud Gandomkar ^a   Etemadi, Ali ^a   Nejati Koshki, Kazem ^a   Zarghami, Nosratallah ^a,b,c   Barkhordari, Amin ^a  

^a Faculty of Science   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

17DMAG; HSP90; Lung cancer; PEG; PLGA; Real time PCR

Indexed keywords

17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; DRUG CARRIER; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; NANOPARTICLE;

CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE;

BENZOQUINONES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LUNG NEOPLASMS; NANOPARTICLES; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 84911134369     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.20.8693     Document Type: Article

References (43)

1. Akbarzadeh A, Hosseininasab S, Davaran S, et al (2014). Synthesis, characterization, and In vitro studies of PLGAPEG nanoparticles for oral Insulin delivery. Chem Biol Drug Des, 3, 1-9.
2. Akbarzadeh A, Mikaeili H, Zarghami N, et al (2012). Preparation and in-vitro evaluation of doxorubicin-loaded Fe3O4 magnetic nanoparticles modified with biocompatible copolymer. Int J Nanomedicine, 7, 1-16.
3. Akbarzadeh A, Nejati-Koshki K, Mahmoudi Soghrati M, et al (2013). In vitro studies of NIPAAM-MAA-VP copolymercoated magnetic nanoparticles for controlled anticancer drug release. JEAS, 3, 108-15.
4. Abarzadeh A, Omidfar K, Ahmadin A, et al (2014). An electrochemical immunosensor for digoxin using core-shell gold coated magnetic nanoparticles as labels. Mol Biol Rep, 41, 1659-68.
5. Akbarzadeh A, Rezaei A, Nejati-Koshki K, et al (2014). Synthesis and physicochemical characterization of biodegradable star-shaped poly lactide-co-glycolide- β -cyclodextrin copolymer nanoparticles containing albumin. J Adv Nanoparticles, 3, 1-9.
6. Akbarzadeh A, Rezaei-Sadabady R, Zarghami N, et al (2013). Studies of the relationship between structure and antioxidant activity in interesting systems, including tyrosol, hydroxytyrosol derivatives indicated by quantum chemical calculations. Soft, 2, 13-8.
7. Akbarzadeh A, Samiei M, Davaran S, et al (2012). Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine. Nanoscale Res Lett, 7, 14-26.
8. Akbarzadeh A, Samiei M, Joo SW, et al (2012). Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnol, 10, 46-52.
9. Akbarzadeh A, Zarghami N, Mikaeili H, et al (2012). Synthesis, characterization and in vitro evaluation of novel polymercoated magnetic nanoparticles for controlled delivery of doxorubicin. Nanotechnol Sci Appl, 5, 13-25.
10. Bagatell R, Whitesell L (2004). Altered Hsp90 function in cancer: a unique therapeutic opportunity. Molecular Cancer Therapeutics, 3, 1021-30.
11. Banerji U (2009). Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15, 9-14
12. Benzo R, Wigle D, Novotny P, et al (2011). Preoperative pulmonary rehabilitation before lung cancer resection: Results from two randomized studies. Lung Cancer, 74, 441-5.
13. Breuer RH, Postmus PE, Smit EF (2005). Molecular pathology of non-small-cell lung cancer. Respiration, 72, 313-30.
14. Chiosis G, L Neckers (2006). Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chemical Biology, 1, 279-84.
15. Crandall K, Maguire R, et al (2014). Exercise intervention for patients surgically treated for Non-Small Cell Lung Cancer (NSCLC): A systematic review. Surg Oncol, 23, 17-30.
16. Dilnawaz F, Singh A, Mohanty C, Sahoo SK (2010). Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials, 31, 3694-706.
17. Dobo C, Stavale JN, de Oliveira Lima F, et al (2013). HSP27 is commonly expressed in cervical intraepithelial lesions of Brazilian Women. Asian Pac J Cancer Prev, 14, 5007-10
18. Ebrahimnezhad Z, Zarghami N, Keyhani M, et al (2013). Inhibition of hTERT gene expression by silibinin-loaded PLGA-PEG-Fe3O4 in T47D breast cancer cell line. Bioimpacts, 3, 67-74.
19. Fukuyo Y, Hunt CR, Horikoshi N, et al (2010). GeldanamycinGhasemaliGhasemali and its anti-cancer activities. Cancer letters, 290, 24-35.
20. Ghasemali S, Nejati-Koshki K, Tafsiri E, et al (2013). Inhibitory effects of -cyclodextrin-helenalin complexes on H-TERT gene expression in the T47D breast cancer cell line-results of real time quantitative PCR. Asian Pac J Cancer Prev, 14, 6949-53.
21. Guo W, Siegel D, Ross D, et al (2008). Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal catalyzed oxidation. J Pharm Sci 97, 5147-57.
22. Hussain SP, Hofseth LJ, Harris CC (2001). Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer, 34, 7-15
23. Jemal A, Siegel R (2008). Cancer statistics, 2008. CA: A Cancer J Clin, 58, 7-96.
24. Karkoulis PK, Stravopodis DJ, Margaritis LH, et al (2010). 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. BMC Cancer, 10, 481.
25. Kouhi M, Vahedi A, Akbarzadeh A, Hanifehpour Y, Joo SW, et al (2014). Investigation of quadratic electro-optic effects and electro-absorption process in GaN/AlGaN spherical quantum dot. Nanoscale research letters, 9, 1-6.
26. Makhnevych T, Houry WA (2012). The role of Hsp90 in protein complex assembly. Biochim Biophys Acta, 1823, 674-82.
27. Mestril R, Batey J (2014). Heat shock proteins protect skeletal muscle against frostbite injury. FASEB J, 28, 1102-43.
28. Mirakabad FT, Akbarzadeh A, Zarghami N, Zeighamian et al., (2013). PLGA-based nanoparticles as cancer drug delivery systems. In: 1st Tabriz international life science conference and 12th Iran biophysical chemistry conference, Tabriz university of medical sciences.
29. Mollazade M, Nejati-Koshki K, Akbarzadeh A, Hanifehpour Y, et al (2013). PAMAM dendrimers arugment inhibitory effect of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Pre, 14, 6925-8.
30. Parkin DM, Bray F (2005). Global cancer statistics, 2002. CA: A Cancer J Clin, 55, 74-108.
31. Pearl LH, Prodromou C, Workman P (2008). The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J, 410, 439-53.
32. Pick E, Kluger Y, Giltnane JM, et al (2007). High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res, 67, 2932-7.
33. Pourhassan-Moghaddam M, Rahmati-Yamchi M, Akbarzadeh A, et al (2013). Protein detection through different platforms of immuno-loop-mediated isothermal amplification. Nanoscale Res Lett, 8, 1-11.
34. Richardson PG, Mitsiades CS, Laubach JP, et al (2011). Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol, 152, 367-79.
35. Qu Z, Dong H, Xu X, Feng W, Yi X (2013). Combined effects of 17-DMAG and TNF on cells through a mechanism related to the NF-kappaB pathway. Diagn Pathol, 8, 70.
36. Röhl A, Rohrberg J, Buchner J (2013). The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci, 38, 253-62.
37. Sakthivel K, Kannan N, Angeline A, Guruvayoorappan C (2012). Anticancer activity of Acacia nilotica (L.) Wild. Ex. Delile subsp. indica against Dalton's ascitic lymphoma induced solid and ascitic tumor model. Asian Pac J Cancer Prev 13, 3989-95.
38. Sharp S, Workman P (2006). Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res, 95, 323-48.
39. Shirinbayan V, Roshan VD, et al (2011). Pretreatment effect of running exercise on HSP70 and DOX-induced cardiotoxicity. Asian Pac J Cancer Prev, 13, 5849-55.
40. Sun X, Bristol JA, Iwahori S, et al (2013). Hsp90 Inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in epstein-barr virus-infected cells. J Virol, 87, 10126-38.
41. Tsuda H (2010). Risk assessment studies of nanomaterials in Japan and other countries. Asian Pac J Cancer Prev, 11, 13-4.
42. Wu GQ, Liu NN, Xue XL, et al (2014). Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy. Asian Pac J Cancer Prev, 15, 4153-8.
43. Whitesell L, Lindquist SL (2005). HSP90 and the chaperoning of cancer. Nature Reviews Cancer, 5, 761-72.